Diffuse large B-cell lymphoma (DLBCL) having both t(14;18) and 8q24 translocations is rare. We evaluated the clinical characteristics and prognoses of patients with DLBCL carrying both t(14;18) and 8q24 translocations. A total of 1972 patients with non-Hodgkin's lymphoma were treated in the Adult Lymphoma Treatment Study Group (ALTSG) from 1998 to 2007. Nineteen cases of de novo DLBCL with the dual translocation were identified. The dual translocation was observed in 19 of 394 patients with DLBCL (10 males and 9 females, with a median age of 61 years). The dual translocation was observed significantly more frequently among patients with high lactate dehydrogenase levels, B symptoms, bone marrow involvement and advanced stage. Immunophenotyping was performed and showed DLBCL with a germinal center type in the majority of cases. Progression-free survival and overall survival rates were significantly lower in patients with the dual translocation than in those with other translocation. DLBCL patients with concurrent t(14;18) and 8q24 translocations have very poor prognosis. Even if patients had a complete response to chemotherapy, they subsequently suffered early relapse. In this study, only a few patients received rituximab, and its usefulness could not be assessed. Future studies with larger numbers of patients are required.
Introduction
Diffuse large B-cell lymphoma (DLBCL) accounts for approximately 40-50% of non-Hodgkin's lymphomas (NHLs). However, DLBCL has heterogeneous clinical, histological and molecular features. It has been established that the clinical features and treatment responses of DLBCL are dependent on genetic and molecular features that modify disease aggressiveness. Gene rearrangements (such as those involving BCL-2, BCL-6 or c-MYC) and protein expression (such as Bcl-2 or Bcl-6) have been shown to have major prognostic value. 1, 2 The t(8;14)(q24;q32) translocation juxtaposes the c-MYC protooncogene, which is located at 8q24, with the immunoglobulin heavy chain (IGH) gene, located at 14q32, resulting in deregulated expression of c-MYC. This results in overexpression of c-MYC, driving cell proliferation and expression of other genes involved in cell growth. 3 The t(8;14)(q24;q32) translocation has been found in 80-90% of Burkitt lymphoma (BL) cases and in 5-15% of DLBCL cases. 4, 5 On the other hand, the t(14;18)(q32;q21) translocation, which juxtaposes the BCL-2 gene, normally located at 18q21, with the IGH locus on 14q32. The t(14;18)(q32;q21) translocation occurs in about 80-90% of follicular lymphomas and about 25-30% of de novo DLBCLs. 6 In recent years, patients with DLBCL with concurrent t(14;18)(q32;q21) and 8q24 translocations have been reported. 7, 8 Le Gouill et al. 7 reported 16 cases of DLBCL with t(14;18) and 8q24 translocations. In their report, DLBCL with t(14;18) and 8q24 translocations showed germinal center profile in all cases and a poor outcome. This study describes the clinical and pathological features of 19 cases of DLBCL with concurrent t(14;18) and 8q24 translocations.
Patients and methods

Patients
A total of 1972 patients with NHL were treated in the Adult Lymphoma Treatment Study Group (ALTSG) in Japan from 1998 to 2007. Chromosomal data were available in 677 (58%) of the 1168 patients with DLBCL. Among them, 394 patients (58%) who had abnormal karyotypes were evaluated. Pathologic evaluation of the materials from each patient was performed at several central review meetings by six hematopathologists in the ALTSG pathology review board. A consensus diagnosis on each patient was obtained using the new World Health Organization (WHO) classification. All patients were newly diagnosed, were previously untreated and received anthracycline-containing combination chemotherapy. Briefly, the CyclOBEAP (cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, prednisone) regimen 9 was primarily administered to younger patients (p60 years old) with DLBCL, and the CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) regimen was primarily administered to older patients (460 years old). Rituximab (R) was additionally administered to six patients who were diagnosed after 2005. The median follow-up period was 64 months (range: 18-90). Informed consent was obtained from patients according to the Declaration of Helsinki Principles.
Methods
Cytogenetic studies
We used the standard technique for chromosome analysis. 10 Biopsied lymph nodes or other tumors were immediately disaggregated with scalpels in RPMI 1640 medium, and single cells were suspended in RPMI 1640 medium supplemented with 20% fetal bovine serum at a concentration of 10 6 cells/ml. 0 of BCL2 exon 3 or in the minor cluster region located about 30 kb 3 0 to the major breakpoint region. The remaining BCL2 breakpoints are thought to lie between the major breakpoint region and minor cluster region, or 5 0 of the BCL2 gene.
Immunohistochemistry
Paraffin-embedded sections of each sample were immunostained with monoclonal antibodies against CD5, CD10, CD20 (Novocastra, Newcastle, UK), BCL2 (DAKO, Glostrup, Denmark), BCL6 (Novocastra), MUM-1 (DAKO) and Mib-1 (Novocastra). The 19 cases were assigned to the germinal center B-cell-like (GCB) group or the non-GCB group according to the classification method of Hans et al. 12 In the immunostaining study using each antibody, the following categories were defined negative (o30% positively stained tumor cells) and positive (X30% positively stained tumor cells).
The presence of Epstein-Barr virus small RNAs (EBER) was determined by in situ hybridization using Epstein-Barr virus-encoded small nuclear early-region oligonucleotides on formalin-fixed, paraffin-embedded sections.
Response to chemotherapy
Tumor response was assessed after 12 weeks of chemotherapy or at the end of treatment, and was classified as complete response (CR), partial response, stable disease or progressive disease according to the International Workshop criteria. 13 
Statistical analysis
All statistical analyses were performed with SAS software (version 9, SAS Institute, Cary, NC, USA). Progression-free survival (PFS) was calculated from the date of beginning chemotherapy to the date of progression or relapse or to the date of the last contact. Overall survival (OS) was calculated from the date of beginning chemotherapy to the date of death from any cause or to the date of the last contact. OS and PFS were used as parameters, and analysis was performed according to the Kaplan-Meier method. The significance of differences in survival was assessed by the log-rank and generalized Wilcoxon tests. Differences between groups were evaluated by the Mann-Whitney U-test (nonparametric analysis).
Results
Clinical characteristics
The t(14;18) þ 8q24 dual translocation was seen in 19 (4.8%) of the 394 patients with DLBCL with abnormal karyotypes. The patients were divided into the following four groups and their clinical characteristics were compared: patients with t(14;18) þ 8q24 dual translocation (n ¼ 19), t(14;18) translocation without 8q24 translocation (n ¼ 18), 8q24 translocation without t(14;18) (n ¼ 24) and those with other chromosomal abnormalities (n ¼ 333) ( Table 1 ). There were no significant differences in age, gender, performance status and international prognostic index 14 among the four groups. Advanced stage, high serum lactate dehydrogenase level, extranodal sites, B symptoms and bone marrow involvement were significantly more prevalent among patients with the dual translocation than among those in the other three groups. The CR rate was 53% (10/19) among patients with the dual translocation and 86.7% (325/375) among patients with other translocations (Po0.001). Among the 19 patients with the dual translocation, extranodal sites of disease were bone marrow (16 patients), central nervous system (4 patients), pleural effusion (6 patients), stomach (2 patients), small intestine (2 patients), lung (1 patient), thyroid (1 patient) and breast (1 patient). Furthermore, 12 patients had at least two extranodal localizations ( Table 2 ).
All 19 patients received chemotherapy. We administered CyclOBEAP therapy to six patients, CHOP therapy to seven patients, R-CHOP therapy to three patients and R-CyclOBEAP therapy to three patients. We added high-dose methotrexate in four patients who presented central nervous system involvement. After induction chemotherapy, 10 and 7 patients achieved CR and partial response, respectively.
Morphological and immunophenotypic findings
The morphology of the tumor cells was consistent with the diagnosis of DLBCL according to the WHO classification in all 19 cases with the dual translocation. Figure 1 shows the morphological features in two patients with the t(14;18) þ 8q24 dual translocation.
The immunohistochemical findings in 19 patients are summarized in Table 3 . All lymphoma cells were positive for CD20 and negative for CD3. CD5 was positive in 2 (10.5%) patients with the dual translocation and in 38 (11.3%) of the 333 patients with other chromosomal abnormalities. The CD10-positive rate was higher in the dual translocation group (84.2%) than in the other chromosomal abnormalities group (12.5%) (Po0.001). BCL-2 was positive in 100% of the patients with dual translocation and in 45% of the patients with other chromosomal abnormalities (Po0.001). BCL-6 was positive in 63.2% of the patients with dual translocation and in 55% of the patients with other chromosomal abnormalities (NS). The MUM-1-positive rate was lower in the dual translocation group than in the other chromosomal abnormalities group (10.5 vs 42%, P ¼ 0.007). Ki-67 staining ranged from 50 to 99% among the 19 patients with the dual translocation. EBER was negative in all 19 dual translocation patients. When the dual translocation patients were divided into the GCB group and the non-GCB group, the GCB group consisted of 16 patients (84.2%) and the non-GCB group consisted of 3 patients. Among the patients in the other chromosomal abnormalities group, 55.8% were in the GCB group (P ¼ 0.02).
Cytogenetic and FISH findings
Cytogenetic findings showed t(14;18) translocation in 17 of 19 patients (Table 4 ). In two patients (cases 13 and 15), cytogenetic findings suggested a 14q32 translocation that was confirmed by FISH. Among the 19 patients with DLBCL with 8q24 translocation, IG-type translocation was seen in 11 patients, including 7 with t(8;14)(q24;q32), 2 with t(8;22)(q24;q11) and 2 with t(2;8)(p11;q24) translocations, and non-IG type translocation was seen in the 8 patients with der(8)(q24). In addition to t(14;18) and 8q24 translocations, one patient had a 17p11 translocation (case 3) and two patients had a 7p13 translocation (cases 2 and 7). Three patients had a complex karyotype, t(8;14;18)(q24;q32;q21) (cases 1, 11 and 17). 
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Lymph node tissue was used for FISH analysis in 11 patients (cases 2-4, 6, 9, 11-13, 15, 16 and 18) and bone marrow in 3 patients (cases 8, 10 and 14). In each specimen, a total of 200 interphase cells were systematically analyzed. In all 14 patients assessed for both c-MYC translocation and IgH/BCL2 fusion, and both abnormalities were identified.
Comparison of OS and PFS among the dual translocation group and the groups with other chromosomal abnormalities among the patients with DLBCL
The survival curves of the dual translocation group (n ¼ 19), t(14;18) translocation without the 8q24 translocation group (n ¼ 18), 8q24 translocation without the t(14;18) translocation group (n ¼ 24) and the other chromosomal abnormalities group (n ¼ 333) are shown in Figure 2 . The 2-year OS rate was 23.3% among the patients with dual translocation, 81.3% among the patients in the t(14;18) translocation group, 65.2% among the patients in the 8q24 translocation group and 83.7% among the patients in the other chromosomal abnormalities group (P ¼ 0.001) (Figure 2a) . The 2-year PFS rate was 0% among the patients with dual translocation, 69.8% among the patients in the t(14;18) translocation group, 36.1% among the patients in the 8q24 translocation group and 62.1% among the patients in the other chromosomal abnormalities group (P ¼ 0.001) (Figure 2b ). The DLBCL progressed during initial therapy in two patients with dual translocation. We performed autologous stem cell transplantation in three patients (cases 2, 4 and 13). The status at the time of transplantation was CR in all three patients. The median PFS and x400 x400 x200 x200 x200 Immunohistochemically, the proliferating cells were CD20 þ (b), BCL-2 þ , CD3eÀ, and CD10 þ (c). The MIB-1 (anti-Ki-67) index was estimated to be approximately 90% (d). The EBER was negative (e).
Table 3
Immunohistochemistry
Abbreviations: BM, bone marrow; EBER, Epstein-Barr virus small RNAs; ISH, in situ hybridization; GC, germinal center B-cell type; LN, lymph node.
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OS among the 19 patients were 14 and 18 months, respectively. Six patients received rituximab in association with chemotherapy. The median PFS and OS of the patients who underwent rituximab combination chemotherapy were 14 and 18 months, respectively. On the other hand, the median PFS and OS of the 13 patients who underwent combination chemotherapy without rituximab were 8 and 10 months, respectively.
Discussion
We described 19 patients with DLBCL in which conventional cytogenetics and/or FISH analysis revealed concurrent t(14;18) and 8q24 translocations. Lymphoma with t(14;18) and 8q24 translocations is seen in patients with BL or DLBCL. Kanungo et al. 8 reported that among 14 patients with the dual translocation, 3 patients had DLBCL, 4 patients had BL, 5 patients had Burkitt-like lymphoma and 2 patients had lowgrade B-cell lymphoma. There are approximately 100 reported cases of DLBCL with t(14;18) and 8q24 translocations in the literature. McClure et al. 15 examined c-MYC/IG translocation and BCL2/IGH fusion by the FISH method in 76 patients with DLBCL and found that 2 (3%) patients had dual translocation. Haralambieva et al. 16 examined c-MYC/IG translocation and BCL2/IGH fusion expression by the FISH method in 52 patients with DLBCL and reported that 4 patients (7.7%) presented dual translocation. Our study showed dual translocation of t(14;18) and 8q24 in 19 (4.8%) of 394 patients with DLBCL with abnormal karyotypes, and this prevalence was similar to that in other reports. t(14;18)(q32;q21) is a cytogenetic abnormality associated with follicular lymphoma. Sequential acquisition of t(14;18) Positive  7 45,X,ÀY,der(1)del(1)(p32)add(1)(q21),add(2)(p13),del(4)(q31),add(7)(p13),add (8) with c-MYC translocation has been documented to coincide with transformation from follicular lymphoma to aggressive lymphoma in experiments using transgenic mice. 17 However, the fact that BL and DLBCL can present in some patients as acute onset suggests that dual translocation can occur simultaneously in a subset of these lymphomas. In this study, a patient with the dual translocation who had presented clinicopathological findings of follicular lymphoma was excluded from the 19 patients with dual translocation and was categorized as having de novo DLBCL. In our study, 394 patients with DLBCL, who were registered consecutively in the ALTSG and who had abnormal karyotypes, were divided into four groups, namely those with the dual translocation of t(14;18) and 8q24, those with t(14;18) translocation, those with 8q24 translocation and those with other chromosomal abnormalities. The patients with dual translocation were compared with the patients who presented other chromosomal abnormalities, and many DLBCL patients with dual translocation presented stage IV disease, elevated lactate dehydrogenase level, multiple extranodal sites of disease, B symptoms and bone marrow involvement. The patients with dual translocation had a significantly poor prognosis than those with other translocations. In addition, the patients who achieved CR subsequently suffered early recurrence (3-16 months). The overall poor outcome of these patients appears to be independent of other clinical prognostic factors and is thought to be related to clonal evolution and the synergy of growth promotion by c-MYC and the anti-apoptotic effect of BCL-2 gene dysregulation. The results of this study may be useful when deciding the treatment strategy in patients with dual translocation. The report of Le Gouill et al. 7 also showed very poor prognosis of patients with the dual translocation of t(14;18) and 8q24/c-MYC, with a median PFS of 4 months and OS of 5 months. We administered rituximab combination chemotherapy in six patients in this study. As the median observation period was short, we cannot conclude regarding the effectiveness of rituximab; however, prognostic improvement was not seen in patients who received the rituximab combination chemotherapy.
Hans et al. 12 reported that non-GCB DLBCL had a significantly poorer prognosis than GCB-type DLBCL. Most cases of DLBCL with t(14;18) and 8q24 translocations are classified as GCB-type DLBCL because many DLBCL patients with dual translocation are CD10-positive. Our findings and other studies 7, 8 do not confirm this result in the subgroup of DLBCL with t(14;18) and 8q24 translocations. The 5-year OS of patients with GCB-type DLBCL was 78% compared with 15% among those with non-GCB DLBCL. 12 However, the prognosis of patients with the dual translocation is poor, presumably because the presence of 8q24/ c-MYC translocation obliterates, the prognostic value of the GCB phenotype. In this study, 10 of the 16 CD10-positive patients were also positive for BCL6. In the report of Le Gouill et al.,
7
BCL6 was tested in 6 of the 11 CD10-positive patients, and 5 patients (83%) were positive for BCL6.
The imprecise distinction between BL and DLBCL at diagnosis may lead to inadequate treatment of some patients with aggressive B-cell lymphoma. The diagnosis of BL relies on morphologic findings, immunophenotyping results and cytogenetic features. However, BL and DLBCL can have overlapping morphologic and immunophenotypic features, and both can have the 8q24/c-Myc translocation. 18, 19 Using transcriptional and genomic profiling analysis, two reports highlighted the molecular differences that distinguish BL, atypical BL and DLBCL. 20, 21 In the study by Hummel et al., 20 0% of the cases of molecular BL with IG-MYC had concurrent IGH-BCL2 fusion and BCL6 translocations. On the other hand, 46% of the cases of DLBCL with IG-MYC had concurrent IGH-BCL2 fusion or BCL6 translocations. In that study, the 5-year OS rate of molecular BL was 75% and the 5-year OS rate of DLBCL was 39%. Overall 46% of DLBCL cases with IG-MYC breakpoints had concurrent BCL2 or BCL6 translocations, suggesting that the c-myc breakpoint arose during clonal evolution and conferred clinical aggressiveness. Dave et al. 21 distinguished DLBCL from BL by gene expression profiling and reported that among the nine patients with molecular BL, three patients had dual translocation of t(14;18) and t (8;14) . Most patients with molecular BL did not have dual translocation and the nine patients quoted presented atypical morphology or immunophenotype that did not allow their pathologic classification as BL. CHOP-like regimens are not adequate for these patients. In recent years, the treatment outcome of BL has improved. Hyper-CVAD plus rituximab therapy 22 or CODOX-M/IVAC (Cyclophosphamide, Doxorubicin, Vincristine, high-dose Methotrexate, Ifosfamide, Etoposide, Cytarabine, Vincristine) therapy 23 was administered to patients with BL or B-ALL. The 3-year OS was 89 and 73%, respectively, and 3-year event-free survival was 80 and 64.6%, respectively. Therefore, it may be necessary to develop therapies stronger than the R-CHOP therapy for treatment of DLBCL with dual translocation.
In conclusion, a subgroup of DLBCLs with t(14;18) þ 8q24 dual translocation was characterized by very aggressive clinical presentation, and the majority had histopathological features of GCB-type DLBCL. Our results suggest that dual translocation is a prognostic factor for DLBCL, and such information is useful for planning the treatment strategy.
